和肽素与降钙素原检测在慢性阻塞性肺疾病急性加重期的临床意义

目的:检测血清和肽素(Copeptin)和降钙素原(procalcitonin,PCT)含量的变化,探讨其在慢性阻塞性肺疾病急性加重期(acute exacerbations of chronic obstructive pulmonary disease,AECOPD)中的临床意义。方法:选取62例AECOPD入院患者为观察组,同时选取30例健康体检者作为对照组,动态监测AECOPD患者血清中Copeptin和PCT治疗前后的水平变化。结果:⑴COPD患者急性加重期和稳定期患者血清中Copeptin浓度分别为(28.7±7.1)pmol/L和(12.8±4.2)pmol/L,高于健康对照组的(7.2±1.8)pmol/L(P<0.05);⑵COPD患者急性加重期和稳定期患者血清中PCT浓度分别为(1.80±0.36)g/L和(0.55±0.12)g/L,高于健康对照组的(0.08±0.05)g/L(P<0.05)。结论:⑴血清PCT和Copeptin是COPD急性加重期较好的监测指标,其参与了COPD患者急性期的发病过程;⑵动态检测AECOPD患者血清PCT水平更有助于疾病预后的判断。

Significance of Copeptin and Procalcitonin in Acute Exacerbation Patients with Chronic Obstructive Pulmonary Disease

Objective To explore the clinical value of copeptin and procalcitonin（PCT） in patients with acute exacerbations of chronic obstructive pulmonary disease（AECOPD） by monitoring their serum content changes. Methods Total 62 patients with AECOPD and 30 healthy volunteers were enrolled in this study. The serum concents of copeptin and PCT in all objects were monitored,the changes of copeptin and PCT levels were analyzed before and after treatment. Results （1）The serum copeptin content of COPD patients was （28.7 ±7.1 ） pmol/L and （ 12.8 ±4.2） pmol/L at acute exacerbation phase and stable phase, respectively, and they were both significantly higher than that of healthy control group（7.2 ± 1.8） pmol/L（ P 〈 0.05 ）. （2）The serum PCT content of COPD patients was （ 1.80± 0.36） g/L and （0.55 ± 0. 12） g/L at acute exacerbation phase and stable phase, respectively, and they were both significantly higher than that of healthy control group（0.08 ± 0.05） g/L（P 〈0.05）. Conclusion （1）Serum copeptin and PCT could be the monitored indexs in patients with AECOPD, which are involved in the development of COPD. （2）The dynamic monitoring of PCT is valuable in prognosis assessment of patients with AECOPD.